الفهرس 
Hepatocellular CarcinomaOnly 14 pages are availabe for public view
 |  | from | 146 |  |  |
| | | from | 146 | | |
Abstract
Worldwide, primary liver cancer is the second and sixth leading cause of cancer mortality in men and women, respectively. The most frequent cause of HCC is liver cirrhosis due to HCV infection. DAAs therapy has made it possible for most patients with HCV infection to achieve a sustained virological response, even if they cannot tolerate interferon-based therapy. The introduction of DAA therapy is expected to improve the prognosis of patients with liver cirrhosis due to HCV infection, and it is also expected that the recurrence rate will decrease in patients after HCC treatment. However, recent studies have suggested that DAA therapy might increase the risk of HCC recurrence. Although DAAs have been demonstrated to lower carcinogenicity in patients without a history of HCC treatment, the effect of DAAs for preventing recurrence after HCC treatment has not been proven. The last few years have seen a major step forward in the treatment of HCV with the introduction of alloral therapies. Direct-acting antiviral agents (DAAs)have since revolutionized the management of HCV patients, achieving high eradication rates with an excellent safety profile. However, there is scarcity in the published literature that directly assess the potentiality of HCC recurrence after DAA therapy among Egyptians, thus we conducted this observational study to assess the potentiality of HCC recurrence and assessment of survival (disease free survival and overall survival) in previously treated HCC patients with local intervention approaches after anti-hepatitis c virus therapy (DAAs).